Breast implant maker Establishment Labs yesterday priced its initial public offering at $18 per share, saying it expects to gross nearly $67 million not including a possible underwriters option.
Alajuela, Costa Rica-based Establishment Labs originally registered the offering at $58 million, saying it plans to use the proceeds to fund a pre-market approval study of its Motiva implants. The FDA granted an investigational device exemption in March for the PMA study and enrolled the first patient the next month, the company said.
Post-market data from sales of Motiva, which it’s sold outside the U.S. since October 2010, show “low rates of adverse events (including rupture, capsular contracture, and safety related re-operations) that we believe compare favorably with those of our competitors,” the company has said.
“We believe the proprietary technologies that differentiate our Motiva implants enable improved safety and aesthetic outcomes and have helped drive our revenue growth. Our MotivaImagine platform enables surgical techniques that we promote as Motiva-branded surgeries. We have developed other complementary products and services on our MotivaImagine platform, which are aimed at further enhancing patient outcomes,” the company said in a registration filing.
Establishment Labs posted net losses of -$34.9 million last year, up 57%, on sales of $34.7 million, up 75.3% compared with 2016. First-quarter losses rose 30% to -$6.5 million on sales growth of 114% to $14.8 million, the company said.
Early rates for DeviceTalks Boston end August 15th.
Don't miss the chance to save $100 and join top medtech innovators including leaders from Hologic, Google, Gray Matter, TransEnterix, NxStage Medical, Smith & Nephew, HeartFlow, Dynatronics, Johnson & Johnson, Allied Minds, and many more.
View Full Agenda
Register today to save. Use code LASTCALL to save an additional 10%.